N-Acyl amino acids and N-acyl neurotransmitter conjugates: Neuromodulators and probes for new drug targets

British Journal of Pharmacology

Volumn 160, Issue 8, 2010, Pages 1857-1871

  Connor, Mark ^a,b   Vaughan, Chris W ^c   Vandenberg, Robert J ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d University of Sydney   (Australia)

Author keywords

analgesics drugs; anti inflammatory drugs; calcium channels; cannabinoids; glycine; molecular pharmacology; neuropharmacology; other transporters; pain; transient receptor potential channels

Indexed keywords

4 AMINOBUTYRIC ACID; ACETURIC ACID; AMINO ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DOPAMINE; G PROTEIN COUPLED RECEPTOR; GLYCINE; GLYCINE RECEPTOR; GLYCINE TRANSPORTER; ION CHANNEL; LIPID; LONG CHAIN FATTY ACID; MEMBRANE PROTEIN; N ACYLDOPAMINE; N ACYLTAURINE; N ARACHIDONOYL GAMMA AMINOBUTYRIC ACID; N ARACHIDONOYLALANINE; N ARACHIDONOYLSERINE; NEUROTRANSMITTER; POTASSIUM CHANNEL; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMINO ACID; CARRIER PROTEIN; FATTY ACID; LIGAND; NEUROTRANSMITTER RECEPTOR;

BINDING AFFINITY; BINDING SITE; CONJUGATE; CONJUGATION; IMMUNE SYSTEM; LIGAND BINDING; NERVOUS SYSTEM; NEUROMODULATION; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ACYLATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION;

ACYLATION; AMINO ACIDS; ANIMALS; BINDING SITES; CARRIER PROTEINS; FATTY ACIDS; HUMANS; ION CHANNELS; LIGANDS; MOLECULAR STRUCTURE; NEUROTRANSMITTER AGENTS; RECEPTORS, NEUROTRANSMITTER; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954876724     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00862.x     Document Type: Review

References (84)

1. Ahern GP (2003). Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 278 : 30429 30434.
2. Alexander SPH, Mathie A, Peters JA (2009). Guide to receptors and channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S101.
3. Almasi R, Szoke E, Bolcskei K, Varga A, Riedl Z, Sandor Z et al. (2008). Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo. Life Sci 82 : 644 671.
4. Aneetha H, O'Dell DK, Tan B, Walker JM, Hurley TD (2009). Alcohol dehydrogenase-catalysed in vitro oxidation of anandamide to N-arachidonoyl glycine, a lipid mediator: synthesis of N-acyl glycinals. Bioorg Med Chem Lett 19 : 237 241.
5. Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinet E et al. (2009). T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J Neurosci 29 : 13106 13114.
6. Barrett CF, Liu L, Rittenhouse AR (2001). Arachidonic acid reversibly enhances N-type calcium current at an extracellular site. Am J Physiol Cell Physiol 280 : 1306 1318.
7. + current. J Biol Chem 278 : 46188 46194.
8. Bezuglov V, Bobrov M, Gretskaya N, Gonchar A, Zinchenko G, Melck D et al. (2001). Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg Med Chem Lett 11 : 447 449.
9. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351 : 817 824.
10. Bradshaw HB, Rimmerman N, Krey JF, Walker JM (2006). Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am J Physiol Regul Integr Comp Physiol 291 : R349 R358.
11. Bradshaw HB, Rimmerman N, Hu SS-J, Benton VM, Stuart JM, Masuda K et al. (2009a). The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem 10 : 14.
12. Bradshaw HB, Rimmerman N, Hu SS-J, Burstein S, Walker JM (2009b). Novel endogenous N-acyl glycines: identification and characterization. In : Gerald Litwack G (ed.). Vitamins Hormones, Volume 81: Anandamide An Endogenous Cannabinoid. Academic Press
13. Burstein SH, Rossetti RG, Yagen B, Zurier RB (2000). Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 61 : 29 41.
14. Burstein SH, Huang SM, Petros TJ, Rossetti RG, Walker JM, Zurier RB (2002). Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem Pharm 64 : 1147 1150.
15. Burstein SH, Adams JK, Bradshaw HB, Fraioli C, Rossetti RG, Salmonsen RA et al. (2007). Potential anti-inflammatory actions of the elmiric (lipoamino) acids. Bioorg Med Chem 15 : 3345 3355.
16. Butelman ER, Ball JW, Harris TJ, Kreek MJ (2003). Topical capsaicin-induced allodynia in unanaesthetized primates: pharmacological modulation. J Pharmacol Exp Ther 306 : 1106 1114.
17. Butelman ER, Harris TJ, Kreek MJ (2004). Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanaesthetized primates. J Pharmacol Exp Ther 311 : 155 163.
18. Cascio MG, Minassi A, Ligresti A, Appendino G, Burstein S, Di Marzo V (2004). A structure activity relationship on N-arachidonoyl amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Comm 314 : 192 196.
19. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P (2001). Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 20 : 7033 7040.
20. Chemin J, Nargeot J, Lory P (2007). Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J Biol Chem 282 : 2314 2323.
21. Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD et al. (2003). N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 278 : 13633 13639.
22. Chu Z-L, Carroll C, Chen R, Alfonso J, Gutierrez V, He H et al. (2010). N-oleoyldopamine enhances glucose homeostasis through activation of GPR119. Mol Endocrinol 24 : 161 170.
23. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 : 83 87.
24. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Marzo D (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483 : 52 56.
25. De Petrocellis L, Chu CJ, Moriello AS, Kellner JC, Walker JM, Di Marzo V (2004). Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid (TRPV1) channels. Br J Pharmacol 143 : 251 256.
26. 1 receptors and endovanilloids. Exp Cell Res 313 : 1911 1920.
27. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 : 1946 1949.
28. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C et al. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 : 686 691.
29. Edington AR, McKinzie AA, Reynolds AJ, Kassiou M, Ryan RM, Vandenberg RJ (2009). Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport. J Biol Chem 284 : 36424 36430.
30. Fowler CJ (2003). Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents: non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid psychotropic effects. Brain Res Rev 41 : 26 43.
31. + channels. J Pharmacol Exp Ther 328 : 351 361.
32. Guo J, Ikeda SR (2004). Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Mol Pharmacol 65 : 665 674.
33. Guo J, Williams DJ, Ikeda SR (2008). N-arachidonyl serine, a putative endocannabinoid, alters the activation of N-type calcium channels in sympathetic neurons. J Neurophysiol 100 : 1147 1151.
34. Harmar AJ, Hills RA, Rosser EM, Jones M, Buneman OP, Dunbar DR et al. (2009). IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucl Acids Res 37 : D680 D685.
35. Herradon E, Martin MI, Lopez-Miranda V (2007). Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol 152 : 699 708. (Pubitemid 350034972)
36. Hu SS-J, Bradshaw HB, Benton VM, Chen JS-C, Huang SM, Minassi A et al. (2009). The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukot Essent Fatty Acids 81 : 291 301.
37. Huang SM, Bisogno T, Petros TJ, Chang S-Y, Zavitsanos PA, Zipkin RE et al. (2001). Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 276 : 42639 42634.
38. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, de Petrocellis L, Fezza F et al. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid receptors. Proc Natl Acad Sci USA 99 : 8400 8405.
39. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96 : 14136 14141.
40. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152 : 825 831.
41. Jordt S-E, Julius D (2002). Molecular basis for species-specific sensitivity to 'hot' chili peppers. Cell 108 : 421 430.
42. 2+ inhibits glycine transport by glycine transporter subtype 1b. J Biol Chem 279 : 22983 22991.
43. Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K et al. (2006). Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Comm 347 : 827 832.
44. Liu L, Barrett CF, Rittenhouse AR (2001). Arachidonic acid both inhibits and enhances whole cell calcium currents in rat sympathetic neurons. Am J Physiol Cell Physiol 280 : 1293 1305.
45. Lundbaek JA (2008). Lipid bilayer-mediated regulation of ion channel function by amphiphilic drugs. J Gen Physiol 131 : 421 429.
46. McCue JM, Driscoll WJ, Mueller GP (2008). Cytochrome c catalyzes the in vitro synthesis of arachidonoyl glycine. Biochem Biophys Res Comm 365 : 322 327.
47. 2. Mol Pharmacol 73 : 441 450.
48. Marinelli S, Di Marzo V, Florenzano F, Fezza F, Viscomi MT, van der Stelt M et al. (2007). N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32 : 298 308.
49. 2 cells. Biochemistry 43 : 12667 12674.
50. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Baktai S et al. (2006). N-arachidonyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA 103 : 2428 2433.
51. Oh DY, Yoon JM, Moon MJ, Hwang J-I, Choe H, Lee JE et al. (2008). Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem 283 : 21054 21604.
52. O'Sullivan SE (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152 : 576 582.
53. O'Sullivan SE, Kendall DA, Randall MD (2004). Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 141 : 803 812.
54. 9-terahydrocannabinol (THC), anandamide and N-arachidonoyl dopamine in the rat isolated aorta. Eur J Pharmacol 507 : 211 221.
55. Oz M (2006). Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharm Ther 111 : 114 144.
56. Parmar N, Ho W-SV (2010). N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br J Pharmacol 160 : 594 603.
57. Pearlman RJ, Aubrey KR, Vandenberg RJ (2003). Arachidonic acid and anandamide have opposite modulatory actions on the GLYT1 subtype of glycine transporters. J Neurochem 84 : 592 601.
58. Piomelli D, Astarita G, Rapaka R (2007). A neuroscientist's guide to lipidomics. Nat Rev Neurosci 8 : 743 754.
59. Premkumar LS, Qi Z-H, van Buren J, Riasinghani M (2004). Enhancement of potency and efficacy of NADA by PKC-mediated phosphorylation of vanilloid receptor. J Neurophysiol 91 : 1442 1449.
60. Prusakiewicz JJ, Kingsley PJ, Kozak KR, Marnett LJ (2002). Selective oxygenation of N-arachidonoyl glycine by cyclooxygenase-2. Biochem Biophys Res Commun 296 : 612 617.
61. Rimmerman N, Bradshaw HB, Hughes HV, Chen JS-C HSS-J, McHugh D et al. (2008). N-Palmitoyl glycine, a novel endogenous lipid that acts as a modulator of calcium influx and nitric oxide production in sensory neurons. Mol Pharmacol 74 : 213 224.
62. Rimmerman N, Bradshaw HB, Basnet A, Tan B, Widlanski TS, Walker JM (2009). Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors. Prostaglandins Other Lipid Mediat 88 : 10 17.
63. 9-Tetrahydrocannabinol and cannabidiol. J Biol Chem 283 : 16124 16134.
64. Ross HR, Gilmore AJ, Connor M (2009). Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonyl dopamine. Br J Pharmacol 156 : 740 750.
65. Ross RA (2009). The enigmatic pharmacology of GPR55. Trends Neurosci 30 : 156 163.
66. Saghatelian A, Trauger SA, Want EJ, Hawkins EG, Siudzdak G, Cravatt BF (2004). Assignment of endogenous substrates to enzymes by global metabolic profiling. Biochemistry 43 : 14332 14339.
67. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF (2006). A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 45 : 9007 9015.
68. Seuwen K, Ludwig M-G, Wolf RM (2006). Receptors for protons or lipid messengers or both. J Recep Sig Trans Res 26 : 599 610.
69. Sharkey KA, Cristino L, Oland LD, van Sickle MD, Starowicz K, Pittman QJ et al. (2007). Arvanil, anandamide and N-arachidonoyl dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 25 : 2773 2782.
70. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997). Structural requirements for binding of anandamide-type compounds to the rat brain cannabinoid receptor. J Med Chem 40 : 659 667.
71. Singh SK, Yamashita A, Gouaux E (2007). Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448 : 952 956.
72. Sipe JC, Arbour N, Gerber A, Beutler E (2005). Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol 78 : 231 238.
73. Succar R, Mitchell VA, Vaughan CW (2007). Actions of N-arachidonyl- glycine in a rat inflammatory pain model. Mol Pain 3 : 24.
74. Sutton KG, Garrett EM, Rutter AR, Bonnert TP, Jarolimek W, Seabrook GR (2005). Functional characterization of the S512Y mutant vanilloid human TRPV1 receptor. Br J Pharmacol 146 : 702 711.
75. Szolcsanyi J, Sandor Z, Petho G, Varga A, Bolcskei K, Almasi R et al. (2004). Direct evidence for activation and desensitization of the capsaicin receptor by N-oleoyl dopamine on TRPV1-transfected cell line, in gene deleted mice and in the rat. Neurosci Lett 361 : 155 158.
76. Tan B, O'Dell DK, Yu YW, Monn MF, Hughes HV, Burstein S et al. (2010). Identification of endogenous acyl amino acids based on a targeted lipidomics approach. J Lipid Res 51 : 112 119.
77. Tseng C-F, Iwakami S, Mikajiri A, Shibuya M, Hanaoka F, Ebizuka Y et al. (1992). Inhibition of in vitro prostaglandin and leukotriene synthesis by cinnamoyl-β-phenethylamine and N-acyldopamine derivatives. Chem Pharm Bull 40 : 396 400.
78. Vuong LAQ, Mitchell VA, Vaughan CW (2008). Actions of N-arachidonyl-glycine in a rat neuropathic pain model. Neuropharmacology 54 : 189 193.
79. Walpole CSJ, Wrigglesworth R, Bevan S, Campbell EA, Dray A, James IF et al. (1993). Analogs of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic 'A-region'. J Med Chem 36 : 2362 2372. (Pubitemid 23262469)
80. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B (2003). Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424 : 434 438.
81. Wiles AL, Pearlman RJ, Rosvall M, Aubrey K, Vandenberg RJ (2006). N-arachidonyl glycine inhibits the glycine transporter, GLYT2a. J Neurochem 99 : 781 786.
82. Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W et al. (2009). Unique ligand selectivity of the GPR92/LPA5 lysophosphatidic acid receptor indicates a role in human platelet activation. J Biol Chem 284 : 17304 17319.
83. Yang Z, Aubrey KR, Alroy I, Harvey RJ, Vandenberg RJ, Lynch JW (2008). Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. Biochem Pharmacol 76 : 1014 1023.
84. TM assay. J Biol Chem 284 : 12328 12338.